SI-BONE, Inc. (SIBN)
| Market Cap | 906.23M +37.7% |
| Revenue (ttm) | 213.60M +15.3% |
| Net Income | -14.63M |
| EPS | -0.33 |
| Shares Out | 44.82M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,373,824 |
| Open | 21.57 |
| Previous Close | 21.23 |
| Day's Range | 20.19 - 21.99 |
| 52-Week Range | 11.48 - 22.95 |
| Beta | 0.66 |
| Analysts | Strong Buy |
| Price Target | 25.44 (+25.82%) |
| Earnings Date | Nov 2, 2026 |
About SIBN
SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the impla... [Read more]
Financial Performance
In 2025, SI-BONE's revenue was $200.93 million, an increase of 20.19% compared to the previous year's $167.18 million. Losses were -$18.90 million, -38.85% less than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for SIBN stock is "Strong Buy." The 12-month stock price target is $25.44, which is an increase of 25.82% from the latest price.
News
SI-Bone reports Q3 EPS (8c), consensus (13c)
Reports Q3 revenue $55.7M, consensus $55.31M. “Robust third-quarter growth in procedure volumes and active physicians underscores rising demand for our diversified and differentiated platform technolo...
SI-Bone backs FY26 revenue view $231M-$233M, consensus $232.13M
Backs FY26 adjusted EBITDA view positive. Cuts FY26 operating expenses view to up 10.5% from up 12%. The company said, “SI-BONE (SIBN) reaffirms its previously issued 2026 worldwide revenue and…
SI-BONE Earnings Call Transcript: Q3 2026
Q3 revenue grew 14.5% and Adjusted EBITDA rose 32.4%, alongside 19.5% U.S. procedure-volume growth. Onyx alpha launch, new Granite DRGs, and broader physician adoption support expected Q4 growth above 20%; FY 2026 revenue guidance was reaffirmed.
SI-BONE Earnings release: Q3 2026
SI-BONE released its Q3 2026 earnings on November 2, 2026, summarizing the period's financial results.
SI-BONE Slides: Q3 2026
SI-BONE has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 2, 2026.
SI-BONE, Inc. Reports Financial Results for the Third Quarter 2026 and Reaffirms 2026 Revenue Guidance
Delivered ~20 % U.S. procedure volume growth in the third quarter Third Quarter 2026 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $55.7 million, representin...
SI-BONE To Present at UBS Global Healthcare Conference on November 10, 2026
SAN JOSE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, ...
SI-BONE To Report Third Quarter 2026 Financial Results on November 2, 2026
SAN JOSE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ: SIBN), a global leader in developing procedural solutions to address clinical challenges associated with compromised bone, to...
SI-Bone price target raised to $25 from $23 at Truist
Truist raised the firm’s price target on SI-Bone (SIBN) to $25 from $23 and keeps a Buy rating on the shares as part of a broader research note previewing Q3…
SI-Bone announces FDA 510(k) clearance of iFuse Granite Onyx System
SI-Bone (SIBN) announced FDA 510(k) clearance for the iFuse Granite Onyx System. This is SI-Bone’s first product addressing the problem of compromised bone which is intended for use outside the…
SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis
FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density b...
SI-BONE Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The company has evolved into a multi-product platform targeting the pelvis and spine, achieving strong growth and profitability through innovation, expanded reimbursement, and a robust product pipeline. Durable tailwinds from new DRGs, product launches, and operational efficiency are expected to accelerate growth and profitability in the coming years.
SI-BONE To Present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026
SANTA CLARA, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bon...
SI-Bone price target raised to $25 from $24 at UBS
UBS analyst Patrick Wood raised the firm’s price target on SI-Bone (SIBN) to $25 from $24 and keeps a Buy rating on the shares. SI-Bone posted a “solid” print and…
SI-Bone price target raised to $20 from $18 at TD Cowen
TD Cowen analyst Mathew Blackman raised the firm’s price target on SI-Bone (SIBN) to $20 from $18 and keeps a Buy rating on the shares. The firm said with strong…
SI-Bone price target raised to $23 from $21 at Truist
Truist raised the firm’s price target on SI-Bone (SIBN) to $23 from $21 and keeps a Buy rating on the shares. The company delivered accelerating revenue growth, stronger procedures, and…
SI-Bone sees FY26 revenue $231M-$233M, consensus $231.79M
The company is maintaining FY26 gross margin guidance at ~79%, and updating operating expenses guidance to now be ~12% compared to the prior guidance of ~12.5%.
SI-Bone reports Q2 EPS (9c), consensus (15c)
Reports Q2 revenue $56.0M, consensus $55.4M. “Our accelerating growth and expanding profitability reinforces our conviction in the demand for our superior platform technologies and the significant run...
SI-BONE Earnings Call Transcript: Q2 2026
Q2 2026 delivered 15% revenue growth, strong operating leverage, and a narrowed net loss, driven by broad-based demand and new product momentum. Guidance was raised, with multiple catalysts expected in H2 2026, including a new breakthrough device launch and higher reimbursement.
SI-BONE Earnings release: Q2 2026
SI-BONE released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
SI-BONE Slides: Q2 2026
SI-BONE has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 3, 2026.
SI-BONE Quarterly report: Q2 2026
SI-BONE has published its Q2 2026 quarterly earnings report on August 3, 2026.
SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance
Delivered ~15% WW revenue growth and ~ 178% increase in adjusted EBITDA ~ 19% increase in U.S. physician base
SI-Bone initiated with a Buy at UBS
UBS analyst Patrick Wood initiated coverage of SI-Bone (SIBN) with a Buy rating and $24 price target The firm anticipates an innovation supercycle, the analyst tells investors in a research…
SI-Bone initiated with a Buy at UBS
UBS analyst Patrick Wood initiated coverage of SI-Bone (SIBN) with a Buy rating and $24 price target